#1 Clinical Trials Search in Europe

Pf-06480605

PF-06480605 is an investigational drug being studied for the treatment of moderate to severe ulcerative colitis. Clinical trials are evaluating its safety, efficacy, and how the body processes the drug. These studies aim to determine if PF-06480605 could potentially become a new treatment option for patients with this inflammatory bowel disease.

Table of Contents

What is PF-06480605?

PF-06480605 is an investigational drug being developed by Pfizer for the treatment of ulcerative colitis[1]. It is a fully human neutralizing antibody, which means it’s a type of protein designed to target and block specific substances in the body[2]. This drug is still in the research phase and is not yet approved for general use.

How Does PF-06480605 Work?

PF-06480605 works by targeting a protein called TL1A (Tumor Necrosis Factor-like Ligand 1A)[1]. TL1A is part of a family of proteins called tumor necrosis factors (TNF) that are involved in inflammation. By blocking TL1A, PF-06480605 aims to reduce inflammation in the intestines, which is a key problem in ulcerative colitis.

What Conditions Does PF-06480605 Treat?

The main condition that PF-06480605 is being studied for is moderate to severe ulcerative colitis[1][2]. Ulcerative colitis is a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract, particularly in the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding.

Clinical Trials and Research

PF-06480605 has been studied in several clinical trials:

  • A Phase 1 study in healthy volunteers to assess safety, tolerability, and how the drug moves through the body (pharmacokinetics)[3].
  • A Phase 2a study in patients with moderate to severe ulcerative colitis, which looked at the drug’s effectiveness and safety[1].
  • A larger Phase 2b study in adults with moderate to severe ulcerative colitis, comparing different doses of the drug to a placebo[2].
  • A study in healthy Japanese participants to evaluate safety and how the drug behaves in their bodies[4].

These trials are helping researchers understand how well PF-06480605 works, what the best dose might be, and whether it’s safe for patients to use.

Administration and Dosing

PF-06480605 has been tested in different ways:

  • Intravenous (IV) administration: The drug is given directly into a vein. In one study, patients received 500 mg every 2 weeks for a total of 7 doses[1].
  • Subcutaneous (SC) administration: The drug is injected under the skin. Various doses have been tested, including 50 mg, 150 mg, and 450 mg given every 4 weeks[2].

The best dosing regimen is still being determined through ongoing research.

Safety and Side Effects

As with any medication, researchers are carefully monitoring the safety of PF-06480605. They look for:

  • Treatment-emergent adverse events (side effects that appear or worsen after starting the drug)
  • Serious adverse events
  • Changes in laboratory tests, vital signs, and heart measurements (ECGs)
  • Development of antibodies against the drug (which could potentially reduce its effectiveness)[1][2][3][4]

Specific information about side effects is not provided in the available data, as the drug is still in the research phase. More detailed safety information will become available as studies progress.

Future Prospects

PF-06480605 shows promise as a potential new treatment for ulcerative colitis. If the ongoing studies continue to show positive results in terms of effectiveness and safety, it may eventually become a new option for patients who haven’t responded well to other treatments. However, it’s important to remember that the drug is still in the research phase and needs to go through more testing before it can be considered for approval by health authorities[1][2].

Aspect Details
Drug Name PF-06480605
Drug Type Fully human neutralizing antibody against TL1A
Condition Studied Moderate to Severe Ulcerative Colitis
Administration Routes Intravenous (IV) and Subcutaneous (SC)
Dosing Schedules Every 2 weeks (Q2W) or Every 4 weeks (Q4W)
Dose Ranges 50 mg to 800 mg
Primary Outcomes Clinical remission, Safety and tolerability
Secondary Outcomes Endoscopic improvement, Biomarker changes, Pharmacokinetics
Trial Phases Phase 1, Phase 2a, Phase 2b

FAQ

  • What is PF-06480605? PF-06480605 is an experimental drug being tested for treating moderate to severe ulcerative colitis. It is a fully human neutralizing antibody that targets a protein called TL1A, which is involved in inflammation.
  • How is PF-06480605 administered? In clinical trials, PF-06480605 has been administered both intravenously (through a vein) and subcutaneously (under the skin). The dosing schedules vary, with some trials using every 2 or 4 week dosing.
  • What are the main goals of the clinical trials for PF-06480605? The main goals are to evaluate the safety, tolerability, and effectiveness of PF-06480605 in treating ulcerative colitis. Researchers are also studying how the body processes the drug and its effects on various biomarkers of inflammation.
  • What are some of the outcomes being measured in these trials? Key outcomes include clinical remission (improvement in symptoms), endoscopic improvement (healing of the colon lining), changes in inflammatory markers like fecal calprotectin and C-reactive protein, and the development of antibodies against the drug.
  • Are there any known side effects of PF-06480605? As with all investigational drugs, the full side effect profile is not yet known. The clinical trials are carefully monitoring for any adverse events, changes in laboratory values, vital signs, and other safety parameters to better understand the drug's safety profile.

Ongoing Clinical Trials on Pf-06480605

  • Study of RVT-3101 for Treating Moderate to Severe Crohn’s Disease in Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +5

Glossary

  • Ulcerative Colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum.
  • TL1A: A protein involved in inflammation that is targeted by PF-06480605. It stands for Tumor Necrosis Factor-like Ligand 1A.
  • Endoscopic Improvement: Healing of the inner lining of the colon as observed through an endoscope (a thin, flexible tube with a camera).
  • Clinical Remission: A state where the symptoms of ulcerative colitis are significantly reduced or absent, often defined by specific scoring criteria in clinical trials.
  • Fecal Calprotectin: A protein found in stool that can indicate the presence and severity of intestinal inflammation.
  • C-reactive Protein (CRP): A protein produced by the liver in response to inflammation, often measured in blood tests.
  • Anti-drug Antibodies (ADA): Antibodies produced by the body against a medication, which can potentially reduce its effectiveness.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Mayo Score: A scoring system used to assess the severity of ulcerative colitis, considering factors like stool frequency, rectal bleeding, and endoscopic findings.

References

  1. https://clinicaltrials.gov/study/NCT02840721
  2. https://clinicaltrials.gov/study/NCT04090411
  3. https://clinicaltrials.gov/study/NCT01989143
  4. https://clinicaltrials.gov/study/NCT04269538